IraqTuberculosis profile
Population  2016 37 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (0.84–1.7) 3.3 (2.3–4.6)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.02)
Incidence  (includes HIV+TB) 16 (14–18) 43 (37–48)
Incidence (HIV+TB only) 0.016 (0.012–0.02) 0.04 (0.03–0.05)
Incidence (MDR/RR-TB)** 1.2 (0.88–1.5) 3.2 (2.4–4.1)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.84 (0.73–0.94) 5.7 (5–6.5) 6.6 (5.7–7.4)
Males 0.95 (0.83–1.1) 8.3 (7.3–9.4) 9.3 (8.1–10)
Total 1.8 (1.6–2) 14 (12–16) 16 (14–18)
TB case notifications, 2016  
Total cases notified 7 317
Total new and relapse 7 246
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 57%
          - % pulmonary 59%
          - % bacteriologically confirmed among pulmonary 62%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 46% (40–52)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.08 (0.05–0.11)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy 0  
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  360
(270–440)
Estimated % of TB cases with MDR/RR-TB 6.1% (4.4–7.8) 24% (14–34)  
% notified tested for rifampicin resistance 78% 80% 5 699
MDR/RR-TB cases tested for resistance to second-line drugs   56
Laboratory-confirmed cases MDR/RR-TB: 187, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 87, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 91% 8 183
Previously treated cases, excluding relapse, registered in 2015 82% 72
HIV-positive TB cases registered in 2015   0
MDR/RR-TB cases started on second-line treatment in 2014 49% 55
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 23
Funding source: 87% domestic, 7% international, 6% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-24 Data: www.who.int/tb/data